Theodora Hatziioannou

List of Publications by Year
in descending order

48 papers	13,939 citations	136950 32 h-index	206112 48 g-index
79 all docs	79 docs citations	79 times ranked	19819 citing authors

#	Article	IF	Citations
1	Plasma Neutralization of the SARS-CoV-2 Omicron Variant. New England Journal of Medicine, 2022, 386, 599-601.	27.0	371
2	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity, 2022, 55, 998-1012.e8.	14.3	86
3	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature, 2022, 607, 128-134.	27.8	197
4	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. Open Forum Infectious Diseases, 2022, 9, .	0.9	5
5	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. Lancet Microbe, The, 2022, 3, e493-e502.	7.3	22
6	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. MBio, 2022, 13, .	4.1	9
7	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. Journal of Experimental Medicine, 2022, 219, .	8.5	10
8	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. Journal of Experimental Medicine, 2022, 219, .	8.5	6
9	Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. Clinical Infectious Diseases, 2021, 73, e1208-e1211.	5.8	65
10	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. Journal of Infectious Diseases, 2021, 223, 389-398.	4.0	233
11	Enhanced SARS-CoV-2 neutralization by dimeric IgA. Science Translational Medicine, 2021, 13, .	12.4	379
12	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	27.8	1,355
13	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	27.8	1,232
14	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature, 2021, 593, 424-428.	27.8	108
15	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature, 2021, 595, 426-431.	27.8	610
16	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature, 2021, 595, 278-282.	27.8	154
17	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. New England Journal of Medicine, 2021, 384, 2212-2218.	27.0	647
18	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. PLoS Pathogens, 2021, 17, e1009688.	4.7	16

#	Article	IF	Citations
19	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nature Communications, 2021, 12, 4196.	12.8	332
20	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	14.3	230
21	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760.	6.4	80
22	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. Journal of Clinical Virology Plus, 2021, 1, 100028.	1.0	2
23	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature, 2021, 600, 512-516.	27.8	174
24	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell Reports Medicine, 2021, 2, 100164.	6.5	26
25	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine, 2021, 218, .	8.5	283
26	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	27.8	239
27	Replication and single-cycle delivery of SARS-CoV-2 replicons. Science, 2021, 374, 1099-1106.	12.6	49
28	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nature Immunology, 2021, 22, 1503-1514.	14.5	40
29	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. ELife, 2021, 10, .	6.0	36
30	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	27.8	1,742
31	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. Journal of Experimental Medicine, 2020, 217, .	8.5	503
32	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell, 2020, 182, 828-842.e16.	28.9	724
33	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. ELife, 2020, 9, .	6.0	1,239
34	Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity. Journal of Virology, 2019, 93, .	3.4	8
35	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10504-10509.	7.1	14
36	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	4.7	20

#	Article	IF	Citations
37	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. ELife, 2019, 8, .	6.0	6
38	A single gp120 residue can affect HIV-1 tropism in macaques. PLoS Pathogens, 2017, 13, e1006572.	4.7	28
39	Envelope residue 375 substitutions in simianâ€"human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3413-22.	7.1	170
40	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. Cell Host and Microbe, 2014, 16, 412-418.	11.0	47
41	HIV-1â€"induced AIDS in monkeys. Science, 2014, 344, 1401-1405.	12.6	76
42	MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature, 2013, 502, 563-566.	27.8	445
43	Assisted Evolution Enables HIV-1 to Overcome a High TRIM5Î±-Imposed Genetic Barrier to Rhesus Macaque Tropism. PLoS Pathogens, 2013, 9, e1003667.	4.7	32
44	Animal models for HIV/AIDS research. Nature Reviews Microbiology, 2012, 10, 852-867.	28.6	274
45	A macaque model of HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4425-4429.	7.1	150
46	Tetherin-Driven Adaptation of Vpu and Nef Function and the Evolution of Pandemic and Nonpandemic HIV-1 Strains. Cell Host and Microbe, 2009, 6, 409-421.	11.0	391
47	Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3563-3568.	7.1	183
48	Generation of Simian-Tropic HIV-1 by Restriction Factor Evasion. Science, 2006, 314, 95-95.	12.6	140